TFS Capital’s Corvus Pharmaceuticals CRVS Stock Holding History

TFS Capital’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-17,125	Closed	-$356K	–	643
2017 Q1	$356K	Buy	+17,125	New	+$268K	0.12%	329

Other funds holding CRVS

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

TFS Capital's CRVS Position: Q2 2017 in Review

TFS Capital sold out of Corvus Pharmaceuticals (CRVS) in Q2 2017, closing a stake of 17,125 shares — an estimated $356K sold.

TFS Capital first reported a position in CRVS in Q1 2017 and held it in 1 quarter. The position peaked at $356K in Q1 2017. 52 funds tracked by Wall St. Rank hold CRVS as of Q2 2017.

TFS Capital reported no remaining Corvus Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
TFS Capital sold 17,125 Corvus Pharmaceuticals shares in Q2 2017, an estimated $356K.
TFS Capital first reported a position in Corvus Pharmaceuticals in Q1 2017 and held it in 1 quarter.
TFS Capital's Corvus Pharmaceuticals position peaked at $356K in Q1 2017.
52 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2017.

Based on TFS Capital's 13F filing for Q2 2017, filed 11 Aug 2017.